Can erdafitinib treat cholangiocarcinoma?

Erdafitinib (Erdafitinib) is an anti-cancer drug that targets FGFR (fibroblast growth factor receptor) gene mutations. FGFRGene mutations are associated with the occurrence and development of some tumors, including cholangiocarcinoma. Erdafitinib is already approved to treat a type of cancer called metastatic or locally advanced urothelial carcinoma (UC), which typically includes the bladder, urethra and renal pelvis. However, the use of erdafitinib may vary for the treatment of cholangiocarcinoma because drugs targeting FGFR may have different efficacy in different types of cancer. If you or someone you know has cholangiocarcinoma or other cancer, it is best to consult a professional doctor for the most up-to-date and accurate treatment information.